Researchers identified nearly 2,000 peptides released during simulated digestion of royal jelly proteins, with two standout peptides (FRYR and FFRNR) showing strong ACE inhibition and binding affinity surpassing the drug captopril in molecular modeling.
1,983 peptides from one protein sourceSimulated digestion of royal jelly proteins released nearly 2,000 unique peptides, with FRYR and FFRNR validated as ACE inhibitors
What the researchers found
From 1,983 peptides identified in the gastrointestinal digest of royal jelly proteins, 237 had high predicted bioactivity scores (≥0.8). After further screening, 49 soluble candidates were selected, and ACE inhibition was the most commonly predicted function.
Molecular docking showed all 49 peptides bound ACE more strongly (-6.9 to -10.9 kcal/mol) than the positive control captopril (-5.6 kcal/mol). In vitro testing confirmed two top performers: FRYR (IC50 = 608 μmol/L, mixed-type inhibitor) and FFRNR (IC50 = 684 μmol/L, competitive inhibitor). FRYR's superior potency was explained by its unique ability to coordinate with the zinc catalytic center of ACE — the same site that pharmaceutical ACE inhibitors target.
Why it matters
Royal jelly is already a popular health food supplement, and demonstrating that its proteins release ACE-inhibiting peptides during normal digestion adds scientific backing to potential cardiovascular benefits. The study is also notable for its systematic methodology — combining peptidomics with computational screening — which represents a modern, efficient approach to discovering food-derived bioactive peptides that could be applied to any protein source.
How the study worked
Royal jelly proteins were subjected to simulated gastrointestinal digestion. The resulting peptides were identified using LC-MS/MS peptidomics. Computational screening (PeptideRanker, molecular docking, bioavailability prediction) narrowed candidates from 1,983 to 49. The top candidates were validated with in vitro ACE inhibition assays, enzyme kinetics analysis (Lineweaver-Burk plots), and detailed molecular docking to characterize binding mechanisms.
What this study cannot tell us
This is an in vitro and in silico study only — no animal or human testing was performed. The IC50 values (608-684 μmol/L) are relatively high compared to pharmaceutical ACE inhibitors and even compared to some other food-derived peptides. Simulated digestion may not perfectly replicate in vivo conditions. It's unclear whether these peptides would be absorbed intact into the bloodstream at active concentrations. The strong molecular docking scores didn't translate proportionally to in vitro potency, highlighting limitations of computational predictions.
How to read the evidence
This is a discovery-phase study using computational and in vitro methods. While the peptidomics approach is thorough, no animal or human evidence exists for these specific peptides. The findings are preliminary and mechanistic.
When this study was published
Published in 2026, this is a very recent study using current peptidomics and bioinformatics tools for bioactive peptide discovery.
The bigger picture
This study adds royal jelly to the growing list of natural protein sources (alongside milk, fish, soy, and coffee) that release ACE-inhibiting peptides during digestion. The finding that FRYR coordinates with ACE's zinc catalytic center — the same mechanism used by pharmaceutical ACE inhibitors — is mechanistically interesting, even though the peptide's potency is much lower than drugs. The systematic peptidomics-to-validation pipeline demonstrated here is increasingly standard in food bioactive peptide research.
Questions still open
- Do these peptides survive intestinal absorption and reach the bloodstream at concentrations sufficient to inhibit ACE in vivo?
- Could consuming royal jelly in typical supplement doses deliver meaningful amounts of these ACE-inhibiting peptides?
- How do these royal jelly peptides compare in a head-to-head test with the well-established milk-derived lactotripeptides IPP and VPP?
Common questions
Could eating royal jelly actually lower blood pressure?
What does it mean that these peptides 'surpassed captopril' in molecular docking?
Read the original research
Discovery and mechanistic insights into ACE inhibitory peptides from the gastrointestinal digest of royal jelly proteins: peptidomics, bioactivity profiling, in silico screening, and in vitro validation.
Food research international (Ottawa, Ont.), 229, 118476
Citation
Yang, Wanyu; Hu, Xiaodi; Zhang, Tianrong; Zhao, Ming; Li, Qiongmin; Sang, Mengnan; Fan, Jinling; Zhao, Yuan; Zhang, Bin. (2026). Discovery and mechanistic insights into ACE inhibitory peptides from the gastrointestinal digest of royal jelly proteins: peptidomics, bioactivity profiling, in silico screening, and in vitro validation.. Food research international (Ottawa, Ont.), 229, 118476. https://doi.org/10.1016/j.foodres.2026.118476